Abstract
The ability of Staphylococcus aureus to clot plasma through conformational activation of prothrombin by staphylocoagulase is used to distinguish S. aureus from coagulase-negative staphylococci. We show that while the direct thrombin inhibitor dabigatran inhibits staphylocoagulase activity, the clinical use of dabigatran etexilate is not expected to interfere with direct tube coagulase testing.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Benzimidazoles / pharmacology*
-
Blood Coagulation / drug effects
-
Coagulase / antagonists & inhibitors*
-
Dabigatran
-
Enzyme Inhibitors / pharmacology*
-
Humans
-
Staphylococcus aureus / enzymology*
-
beta-Alanine / analogs & derivatives*
-
beta-Alanine / pharmacology
Substances
-
Benzimidazoles
-
Coagulase
-
Enzyme Inhibitors
-
beta-Alanine
-
Dabigatran